Regulatory Compliance

Beijing – September 21, 2026 -- Nearly 390 representatives from 41 countries and regions gathered in Beijing on September 18 for the China Arbitration Summit 2026, an event that drew over 5.14 million online views from 55 countries and regions.

Four institutions co-host flagship dispute-resolution forum

The China High-level Dialogue on Maritime and Commercial Arbitration was jointly organized by the China International Economic and Trade Arbitration Commission (CIETAC), the China Maritime Arbitration Commission (CMAC), the United Nations Commission on International Trade Law (UNCITRAL), and the All China Lawyers Association (ACLA). The summit served as the flagship event of the 14th China Arbitration Week, which ran 77 seminars across 40 cities in 10 countries and regions from September 15 to 21.

Ras Al Khaimah – September 21, 2026 -- ARIDGE, formerly XPENG AEROHT and Asia's largest flying car company, has signed a strategic cooperation agreement with the Emirate of Ras Al Khaimah to establish what both parties describe as the world's first regulatory sandbox dedicated to personal low-altitude flight.

The agreement was signed in the presence of His Highness Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, under oversight of the UAE General Civil Aviation Authority (GCAA). The deal makes ARIDGE the first Chinese flying car company to enter a national-level regulatory sandbox in the Middle East.

Rochester, Mich. – September 21, 2026 -- Par Health is voluntarily recalling two lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection 400 mcg/100 mL (4 mcg/mL) at the hospital level after detecting particulate matter identified as cellulose or stopper material.

Contaminated vials carry risk of pulmonary emboli and vessel occlusion

The FDA-notified recall covers Lots 87558 and 88802, which were distributed nationwide to wholesalers between September 21, 2026 and September 21, 2026. Par Health warned that administering the affected product carries a reasonable probability of causing life-threatening adverse health consequences, including pulmonary emboli, occlusions of other blood vessels that can lead to tissue death and organ damage, and inflammation of vein walls that may result in clotting. The company said it has not received any adverse event reports tied to the recall to date.

Fountain Valley, Calif. – September 21, 2026 -- MemorialCare's Long Beach Medical Center and Saddleback Medical Center have received the American Heart Association's Get With The Guidelines® - Stroke Gold Plus quality achievement award, recognizing stroke treatment aligned with nationally validated clinical guidelines. Long Beach Medical Center additionally earned the Get With The Guidelines® - Heart Failure Gold Plus award for reducing readmissions and increasing healthy days at home for heart failure patients.

Long Beach Medical Center collects four additional Target Honor Roll designations

Long Beach Medical Center received the Target: Stroke Honor Roll Elite Plus, Advanced Therapy, Target: Type 2 Diabetes Honor Roll, and Target: Heart Failure Honor Roll Optimal. Saddleback Medical Center secured the Target: Stroke Honor Roll Elite Plus and Target: Type 2 Diabetes Honor Roll designations.

Sheridan, Wyoming – September 21, 2026 -- The global remote patient monitoring (RPM) market is set to grow from $34.5 billion in 2026 to $62.2 billion by 2031, a 12.5% compound annual growth rate, according to a new study by Wissen Research.

Reimbursement codes and readmission penalties push hospitals toward RPM at scale

Dedicated CMS billing codes are giving U.S. providers a recurring revenue incentive to deploy RPM, while health systems use the technology to avoid costly 30-day readmission penalties tied to chronic disease relapse. Cardiovascular disease held the largest application share in 2025, reflecting the clinical and financial burden of heart failure, atrial fibrillation and hypertension.

Sacramento – September 21, 2026 -- California Governor Gavin Newsom signed an executive order accelerating implementation of SB 813, the Fathom-sponsored law that established the nation's first comprehensive framework for independent verification organizations (IVOs) overseeing frontier AI systems.

California moves IVO designation deadline up by eight months

The executive order shifts the state's deadline to finalize IVO designation criteria from January 2028 to May 2027. SB 813 already created the legal structure for IVOs, third-party bodies tasked with independently assessing AI labs' safety claims.

New York – September 21, 2026 -- Invictus Pharmacy has secured LegitScript Healthcare Merchant Certification for its platform InvictusPharmacy.com, joining a select group of digital pharmacy operators that includes Amazon Pharmacy in meeting the certifier's compliance standards.

LegitScript certification confirms pharmacy licensing and prescription validity standards

The certification evaluates pharmacy licensing, regulatory compliance, patient privacy protocols, valid prescription practices, website transparency and advertising conduct. Invictus Pharmacy's approval places it among established platforms cleared to operate within the regulated digital healthcare marketplace.

Arlington, Va. – – September 21, 2026 -- Info-Tech Research Group has released a new blueprint warning that AI agents embedded in product workflows are making decisions without explicit human authorization, creating governance blind spots for IT organizations shifting to product-centric delivery models.

Silent delegation lets AI agents make product decisions unchecked

The research firm's "Make the Case for Product Delivery" blueprint identifies a phenomenon it calls silent delegation, where AI agents participating in discovery, prioritization, experimentation, delivery, and support can execute decisions without a documented human approval trail. Info-Tech says leaders often lack visibility into where agents are merely recommending actions versus actively executing them, leaving open questions about who can override an agent's decision and who remains accountable for the outcome.

Washington – September 21, 2026 -- The American Association of Kidney Patients (AAKP) has endorsed Health and Human Services Secretary Robert F. Kennedy Jr.'s new appointments to the U.S. Preventive Services Task Force (USPSTF), following a years-long campaign by the group to force reforms on kidney disease screening policy. AAKP President Edward V. Hickey III said the appointees bring the diverse credentials needed to advance patient-centered medicine after what the organization calls two decades of Task Force inaction on kidney health.

Indianapolis – September 21, 2026 -- The U.S. Food and Drug Administration has granted full approval to Eli Lilly and Company's (NYSE: LLY) Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy.

EMBER-3 trial shows combination doubles progression-free survival

The approval rests on Phase 3 EMBER-3 data in 159 patients with ESR1-mutated metastatic breast cancer who had previously received an aromatase inhibitor, with or without a CDK4/6 inhibitor. Patients randomized to Inluriyo plus Verzenio (n=67) achieved a median progression-free survival of 11.1 months, versus 5.5 months for Inluriyo alone (n=92), a hazard ratio of 0.53 (95% CI, 0.35–0.80).